Merck (MRK) PT Lowered to $64 at Bernstein

Jefferies Upgrades Merck (MRK) to Hold

Jefferies upgraded Merck (NYSE: MRK) from Underperform to Hold with a price target of $55.00 (from $54.00).

Analyst Jeffery Holford believes the sharp move lower recently has removed much of the downside he previously suspected would manifest and now moves to the... More

Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'

UBS lowered its price target on Merck (NYSE: MRK) to $67.00 (from $72.00) while maintaining a Buy rating, following the announcement that management would push out results into early 2019 for Keynote-189 in lung cancer.

Analyst Marc Goodman notes a cautious outlook on the shares as... More

Merck (MRK) PT Lowered to $69 at Leerink Partners

Leerink Partners lowered its price target on Merck (NYSE: MRK) to $69.00 (from $70.00) while maintaining a Market Perform rating following results

Analyst Seamus Fernandez said the majority of the bottom-line beat came from other income and a lower-than-anticipated tax rate.

SunTrust Robinson Humphrey Downgrades Merck (MRK) to Hold

SunTrust Robinson Humphrey downgraded Merck (NYSE: MRK) from Buy to Hold with a price target of $54.00 (from $73.00).

Analyst John Boris adjusts his model to account for Keytruda application withdraw and rising competition for Merck.

For an analyst ratings summary and... More

Morgan Stanley Downgrades Merck (MRK) to Equalweight

Morgan Stanley downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $56.00 (from $69.00).

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $58.24 Friday.

Barclays Downgrades Merck (MRK) to Equalweight

Barclays downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $62.00 (from $72.00).

Analyst Geoff Meacham cites limited upside potential for the equity originating from Keytruda which is "by far Meerck's biggest value driver." The analyst notes headwinds to the... More

Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its European application for KEYTRUDA® (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).

... More